CLDX Stock Analysis: Celldex Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.559m USD | 12M Return: 17.5% | US15117B2025 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 53.6M
Qual. Beats: 1
Rev. Trend: -74.1%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Celldex Therapeutics is a US-based clinical-stage biopharmaceutical company that develops monoclonal and bispecific antibodies to treat severe inflammatory, allergic, and autoimmune diseases where existing therapies are inadequate. The companys pipeline is centered on mast cell–mediated conditions, with its lead candidate Barzolvolimab (CDX-0159), a KIT receptor–targeting monoclonal antibody being studied in chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis, alongside CDX-622, a bispecific antibody that neutralizes thymic stromal lymphopoietin (TSLP) while depleting mast cells via stem cell factor starvation. The company is headquartered in Hampton, New Jersey, and is classified within the GICS Biotechnology sub-industry.
As a pre-commercial biotech, Celldex operates a typical pipeline-driven business model in which value is tied to clinical-trial outcomes and regulatory progress rather than product sales, and its mid-cap market capitalization reflects investor expectations tied to the advancement of its antibody candidates.
- Barzolvolimab Phase 3 chronic urticaria data readout expected
- FDA approval timeline for CDX-0159 drives valuation
- Cash burn raises secondary offering dilution risk
| Net Income: -300.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.31 > 0.02 and ΔFCF/TA -3.86 > 1.0 |
| NWC/Revenue: 593k% < 20% (prev 10.6k%; Δ 582k% < -1%) |
| CFO/TA -0.30 > 3% & CFO -235.6m > Net Income -300.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 11.82 > 1.5 & < 3 |
| Outstanding Shares: last quarter (77.8m) vs 12m ago 17.24% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.02% > 50% (prev 0.84%; Δ -0.82% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.85 (Total Current Assets 724.9m - Total Current Liabilities 61.3m) / Total Assets 782.3m |
| B: -2.51 (Retained Earnings -1.97b / Total Assets 782.3m) |
| C: -0.41 (EBIT TTM -300.6m / Avg Total Assets 737.4m) |
| D: 10.54 (Book Value of Equity 714.6m / Total Liabilities 67.8m) |
| Altman-Z'' = 5.70 = AAA |
| DSRI: 3.0 (Receivables 230k/90.0k, Revenue 112k/5.79m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.03 (AQ_t 0.05 / AQ_t-1 0.05) |
| SGI: 0.02 (Revenue 112k / 5.79m) |
| TATA: -0.08 (NI -300.6m - CFO -235.6m) / TA 782.3m) |
| Beneish M = -2.07 (Cap -4..+1) = BB |
As of October 07, 2026, the stock is trading at USD 31.01 with a total of 1,768,232 shares traded. Over the past week, the price has changed by -2.01%, over one month by -20.74%, over three months by -18.30% and over the past year by +17.53%.
Current recommended Stop Loss: 27.20 (which is 12.3% or 2.1 ATR below the current price).
Celldex Therapeutics has received a consensus analysts rating of 4.73. Therefore, it is recommended to buy CLDX.
- StrongBuy: 12
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 63.1 | 103.4% |
P/S = 16197.959
P/B = 3.6838
Revenue TTM = 112k USD
EBIT TTM = -300.6m USD
EBITDA TTM = -297.2m USD
Long Term Debt = 3.35m USD (estimated: total debt 4.90m - short term 1.56m)
Short Term Debt = 1.56m USD (from shortTermDebt, last quarter)
Debt = 4.90m USD (from shortLongTermDebtTotal, last quarter) (leases 4.90m already included)
Net Debt = -712.7m USD (calculated: Debt 4.90m - CCE 717.6m)
Enterprise Value = 1.85b USD (2.56b + Debt 4.90m - CCE 717.6m)
Interest Coverage Ratio = unknown (Ebit TTM -300.6m / Interest Expense TTM 0.0)
EV/FCF = -7.64x (Enterprise Value 1.85b / FCF TTM -241.8m)
FCF Yield = -13.10% (FCF TTM -241.8m / Enterprise Value 1.85b)
FCF Margin = -216k% (FCF TTM -241.8m / Revenue TTM 112k)
Net Margin = -268k% (Net Income TTM -300.6m / Revenue TTM 112k)
Gross Margin = unknown ((Revenue TTM 112k - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 2.36 (Enterprise Value 1.85b / Total Assets 782.3m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 4.90m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -237.5m (EBIT -300.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 11.82 (Total Current Assets 724.9m / Total Current Liabilities 61.3m)
Debt / Equity = 0.01 (Debt 4.90m / totalStockholderEquity, last quarter 714.6m)
Debt / EBITDA = 2.40 (negative EBITDA) (Net Debt -712.7m / EBITDA -297.2m)
Debt / FCF = 2.95 (negative FCF - burning cash) (Net Debt -712.7m / FCF TTM -241.8m)
Total Stockholder Equity = 574.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -40.76% (Net Income -300.6m / Total Assets 782.3m)
RoE = -52.36% (Net Income TTM -300.6m / Total Stockholder Equity 574.1m)
RoCE = -52.06% (EBIT -300.6m / Capital Employed (Equity 574.1m + L.T.Debt 3.35m))
RoIC = -32.86% (negative operating profit) (NOPAT -237.5m / Invested Capital 722.6m)
WACC = 9.67% (E(2.56b)/V(2.56b) * Re(9.69%) + D(4.90m)/V(2.56b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.69% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 70.87 | Cagr: 13.22%
[DCF] Fair Price = unknown (Cash Flow -241.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.11 | # QB: 1
Revenue Correlation: -74.05 | Revenue CAGR: -65.74% | SUE: -0.61 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-1.01 | Chg30d=-0.56% | Revisions=+44% | Analysts=10
EPS current Year (2026-12-31): EPS=-4.12 | Chg30d=-0.43% | Revisions=+67% | GrowthEPS=-5.7% | GrowthRev=+19.7%
EPS next Year (2027-12-31): EPS=-4.24 | Chg30d=-1.78% | Revisions=-40% | GrowthEPS=-2.7% | GrowthRev=+438.1%
[Analyst] Revisions Ratio: +47% (up=11, down=3)